[Onco-cardiology in hematopoietic malignancies].

Abstract

Cancer patients who develop cardiovascular complications have significantly lower survival rates due to their inability to continue appropriate cancer treatment. Onco-cardiology is an interdisciplinary area in which cardiologists and oncologists collaborate to optimize cancer treatment. The goal is to improve the prognosis and quality of life of cancer patients by ensuring that they can continue cancer treatment with appropriate cardiac management. When cardiotoxic anticancer drugs will be used, the oncologist should assess the patient's risk and cardiac function before starting treatment, and adjust treatment based on risk factors. During treatment, cardiac evaluation should be performed according to the patient's risk. Echocardiographic left ventricular ejection fraction (LVEF) is used to assess cancer treatment-related cardiac dysfunction (CTRCD), and global longitudinal strain is considered useful for anthracycline therapy. Troponin I/T and BNP/NT-proBNP are used as biomarkers of cardiac function. When a patient has reduced LVEF, a cardiologist should be consulted for treatment of CTRCD and cardioprotective therapy should be considered.